Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

NCT00035334 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary (AA) Amyloidosis
Rheumatoid Arthritis
Nephrotic Syndrome
Familial Mediterranean Syndrome
Kidney Diseases
Gastrointestinal Diseases

Interventions

DRUG: NC-503 (Anti-amyloidotic (AA) Agent)

Sponsor

Bellus Health Inc. - a GSK company

Collaborators

[object Object]